ZURICH, June 14, 2023 \/PRNewswire\/ -- Switzerland is home to a globally unique life science cluster. In addition to multinational companies like Novartis and Roche, this encompasses a dense network of startups and SMEs. Its renowned universities, strong intellectual property protection and strategic location in the middle of Europe have made Switzerland a preferred site for global and regional pharma headquarters. There is a strong ecosystem in place that feeds a dynamic talent pool and provides companies with an important advantage: All parts of the value chain from R&D to manufacturing, through to commercialization can be accessed in one location. <\/p>\n
SWITZERLAND A THRIVING HUB FOR PERSONALIZED HEALTH <\/p>\n
At the same time, the pragmatic and business-friendly legislation has attracted fastgrowing tech companies that develop high-quality \"Swiss made\" products. For companies who wish to quickly and easily bring new innovations in personalized health to market, Switzerland offers the ideal environment. <\/p>\n
THE ADVANTAGES OF SWITZERLAND <\/p>\n
1. High Innovation Output <\/p>\n
A steady stream of highly qualified talent and scientists in Switzerland make a significant contribution towards developing new medicines. The framework conditions are also in place: The Swiss healthcare system supports the introduction of new medicines and, in doing so, offers companies access to a sophisticated test and sales market. <\/p>\n
Why Switzerland: <\/p>\n
2. Life Sciences Value Chain in One Place <\/p>\n
With its long tradition in life sciences and a strong infrastructure in advanced manufacturing, Switzerland offers a dense and experienced network of peers, universities and suppliers over a geographically manageable terrain. It is precisely because Switzerland is a small country that industry benefits from this experienced cluster along the entire value chain to develop, produce and market new products and services all in one place. <\/p>\n
Why Switzerland: <\/p>\n
3. Strategic Location in the Heart of Europe <\/p>\n
With its strong life sciences clusters and a business-friendly environment, Switzerland has become a favored headquarter location for pharmaceutical companies expanding into Europe for the first time. Its thriving ecosystem provides partnering and licensing opportunities, and the country's geographical position helps access the European market efficiently. <\/p>\n
Why Switzerland: <\/p>\n
4. First-Class Technology <\/p>\n
Swiss authorities are pragmatic and business-friendly, which has led to pioneering regulations in the field of emerging technologies such as blockchain, robotics, or AI. This has attracted global talent and fast-growing tech companies that develop high-quality products. <\/p>\n
Why Switzerland: <\/p>\n
Case Studies <\/p>\n